Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine parainfluenza; leptospira icterohaemorrhagiae antigen; canine adeno virus type 2; canine coronavirus vaccine - antigen; canine distemper virus; canine parvo virus - misc. vaccines or anti sera - canine parainfluenza vaccine active 0.0 undefined; leptospira icterohaemorrhagiae antigen vaccine-antigen active 0.0 undefined; canine adeno virus type 2 vaccine-viral active 0.0 undefined; canine coronavirus vaccine - antigen vaccine-viral active 0.0 undefined; canine distemper virus vaccine-viral active 0.0 undefined; canine parvo virus vaccine-viral active 0.0 undefined - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 10mg - injection with diluent - 10 mg - active: alteplase 10mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 20mg - injection with diluent - 20 mg - active: alteplase 20mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - alteplase 50mg - injection with diluent - 50 mg - active: alteplase 50mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous - aerosol inhaler, metered dose - 20 mcg/dose - active: ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous excipient: citric acid ethanol nitrogen norflurane purified water - atrovent is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema and asthma.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - clonidine hydrochloride 25ug - tablet - 25 mcg - active: clonidine hydrochloride 25ug excipient: acacia amylodextrin calcium hydrogen phosphate dihydrate carnauba wax colloidal silicon dioxide indigo carmine   lactose monohydrate macrogol 6000 magnesium stearate maize starch methyl hydroxybenzoate povidone   propyl hydroxybenzoate purified talc sucrose titanium dioxide white beeswax

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - interferon gamma-1b 200 µg/ml - solution for injection - 3 miu/0.5ml - active: interferon gamma-1b 200 µg/ml excipient: mannitol polysorbate 20 sodium succinate succinic acid water for injection - imukin is indicated as an adjunct for reduction of the frequency of serious infections in patients with chronic granulomatous disease (cgd). the benefits of imukin have been most marked in children with cgd although imukin may be used in adult patients.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - tenecteplase 30mg (recombinant) - powder for injection - 30 mg - active: tenecteplase 30mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - tenecteplase 40mg (recombinant) - powder for injection - 40 mg - active: tenecteplase 40mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) limited - tenecteplase 50mg (recombinant) - powder for injection - 50 mg - active: tenecteplase 50mg (recombinant) excipient: arginine phosphoric acid polysorbate 20 water for injection - metalyse is indicated for the thrombolytic treatment of the acute phase of myocardial infarction (ami). treatment should be initiated as soon as possible after symptom onset. treatment can be initiated within 12 hours of symptom onset.